
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is poised for long-term success with their best-in-class technology and strong management execution, as evidenced by their record domestic Hydros sales and impressive procedure growth. The recent commercial initiatives implemented by newly appointed CEO Larry Wood are likely temporary headwinds, and the company's heavily discounted valuation and upcoming Investor Day provide potential for the stock to outperform.
Bears say
PROCEPT BioRobotics is currently facing several headwinds, including a recent voluntary field action and pricing pressure, which could impact its sales and overall financial performance. Additionally, increased competition in the BPH market could pose a threat to the company's sales and market position. These challenges, coupled with a recent reduction in revenue guidance, suggest a negative outlook for PROCEPT BioRobotics's stock.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares